Galectin3抗体;Galectin3 Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

Galectin-3. a β-galactoside-binding lectin, plays multifunctional roles in cell adhesion, proliferation, apoptosis, and immune regulation. Overexpressed in cancers, fibrotic diseases, and chronic inflammation, it promotes tumor progression, metastasis, and extracellular matrix remodeling. Its unique structure—a carbohydrate-recognition domain linked to a proline-rich N-terminal region—enables interactions with glycoproteins, influencing signaling pathways like Wnt/β-catenin and RAS. These properties make Galectin-3 a compelling therapeutic and diagnostic target.

Antibodies against Galectin-3. primarily monoclonal (e.g., M3/38. B2C10), are designed to block its pathological functions. They bind to specific epitopes, inhibiting ligand interactions or disrupting oligomerization critical for its activity. In research, these antibodies are tools for detecting Galectin-3 in tissues (e.g., cancer biopsies) or serum via immunoassays (ELISA, immunohistochemistry). Clinically, they hold potential for therapeutic intervention. Preclinical studies show that Galectin-3 blockade reduces tumor growth, fibrosis, and inflammation in models of pancreatic cancer, liver fibrosis, and heart failure. Several antibody-based therapies, including F(ab')₂ fragments and humanized versions, are in development to improve pharmacokinetics and reduce immunogenicity.

Challenges remain in optimizing specificity, delivery efficiency, and minimizing off-target effects. Nonetheless, Galectin-3 antibodies represent a promising avenue for precision medicine, particularly in oncology and fibrotic disorders, with ongoing clinical trials exploring their synergy with existing therapies.